PAM
OCUL icon

Panagora Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Panagora Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$939K Buy
95,593
+1,063
+1% +$9.63K ﹤0.01% 755
2026
Q1 		$801K Buy
+94,530
New +$901K ﹤0.01% 762
2025
Q3 		– Sell
-296,546
Closed -$2.75M – 1223
2025
Q2 		$2.75M Buy
296,546
+74,542
+34% +$583K 0.01% 418
2025
Q1 		$1.63M Sell
222,004
-215,733
-49% -$1.66M 0.01% 561
2024
Q4 		$3.74M Buy
437,737
+173,382
+66% +$1.69M 0.02% 398
2024
Q3 		$2.3M Buy
+264,355
New +$2.18M 0.01% 515
2023
Q1 		– Sell
-38,757
Closed -$109K – 1511
2022
Q4 		$109K Buy
38,757
+1,805
+5% +$5.98K ﹤0.01% 1410
2022
Q3 		$153K Sell
36,952
-47,127
-56% -$237K ﹤0.01% 1392
2022
Q2 		$338K Sell
84,079
-1,345
-2% -$5.08K ﹤0.01% 1280
2022
Q1 		$423K Buy
85,424
+55,346
+184% +$307K ﹤0.01% 1273
2021
Q4 		$210K Buy
+30,078
New +$234K ﹤0.01% 1477
2021
Q3 		– Sell
-1,378
Closed -$20K – 2167
2021
Q2 		$20K Buy
1,378
+1,016
+281% +$15.4K ﹤0.01% 2171
2021
Q1 		$6K Hold
362
– – ﹤0.01% 2550
2020
Q4 		$7K Sell
362
-721
-67% -$10.7K ﹤0.01% 2382
2020
Q3 		$8K Sell
1,083
-1,118
-51% -$9.28K ﹤0.01% 2356
2020
Q2 		$18K Hold
2,201
– – ﹤0.01% 2158
2020
Q1 		$11K Sell
2,201
-16,774
-88% -$82.8K ﹤0.01% 2126
2019
Q4 		$75K Buy
+18,975
New +$66K ﹤0.01% 1856
2016
Q2 		– Sell
-3,100
Closed -$30K – 2332
2016
Q1 		$30K Buy
+3,100
New +$23.5K ﹤0.01% 2091

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Panagora Asset Management's OCUL Position: Q2 2026 in Review

Panagora Asset Management increased its Ocular Therapeutix (OCUL) stake by 1.1% in Q2 2026, buying an estimated $9.63K and bringing the position to 95,593 shares worth $939K. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Panagora Asset Management first reported a position in OCUL in Q1 2016 and has held it in 19 quarters since. The position peaked at $3.74M in Q4 2024. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Panagora Asset Management held 95,593 shares of Ocular Therapeutix worth $939K as of Q2 2026.
  • Panagora Asset Management bought 1,063 Ocular Therapeutix shares in Q2 2026, an estimated $9.63K.
  • Ocular Therapeutix made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #755 holding.
  • Panagora Asset Management first reported a position in Ocular Therapeutix in Q1 2016 and has held it in 19 quarters since.
  • Panagora Asset Management's Ocular Therapeutix position peaked at $3.74M in Q4 2024.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.